Risk of Leukemia Among Survivors of Testicular Cancer: A Population-based Study of 42,722 Patients

Annals of Epidemiology

Volumn 18, Issue 5, 2008, Pages 416-421

  Howard, Regan ^a   Gilbert, Ethel ^a   Lynch, Charles F ^b   Hall, Per ^c   Storm, Hans ^d   Holowaty, Eric ^e   Pukkala, Eero ^f   Langmark, Froydis ^g   Kaijser, Magnus ^c   Andersson, Michael ^d   Joensuu, Heikki ^h   Fossa, Sophie D ⁱ   Allan, James M ^j   Travis, Lois B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Iowa Cancer Registry   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^e CANCER CARE ONTARIO   (Canada)

^f FINNISH CANCER REGISTRY   (Finland)

^g CANCER REGISTRY OF NORWAY   (Norway)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

^j NEWCASTLE UNIVERSITY   (United Kingdom)

more..

Author keywords

Cohort Studies; Leukemia; Second Primary Neoplasms; Testicular Neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; CONTROLLED STUDY; FOLLOW UP; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEMINOMA; TESTIS CANCER;

ADULT; COHORT STUDIES; EUROPE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, SECOND PRIMARY; NORTH AMERICA; REGISTRIES; TESTICULAR NEOPLASMS;

EID: 44349172341     PISSN: 10472797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annepidem.2008.01.003     Document Type: Article

References (22)

1. In: Ries L.A.G., Melbert D., Krapcho M., Mariotto A., Miller B.A., Feuer E.J., et al. (Eds). SEER cancer statistics review, 1975-2004 (2006), National Cancer Institute, Bethesda (MD). http://seer.cancer.gov/csr/1975_2004 Available at:
2. Redman J.R., Vugrin D., Arlin Z.A., Gee T.S., Kempin S.J., Godbold J.H., et al. Leukemia following treatment of germ cell tumors in men. J Clin Oncol 2 (1984) 1080-1087
3. Pedersen-Bjergaard J., Daugaard G., Hansen S.W., Philip P., Larsen S.O., and Rorth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ cell tumours. Lancet 338 (1991) 359-363
4. van Leeuwen F.E., Stiggelbout A.M., van den Belt-Dusebout A.W., Noyon R., Eliel M.R., van Kerkhoff E.H., et al. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol 11 (1993) 415-424
5. Travis L.B., Curtis R.E., Storm H., Hall P., Holowaty E., van Leeuwen F.E., et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89 (1997) 1429-1439
6. Travis L.B., Andersson M., Gospodarowicz M., van Leeuwen F.E., Bergfeldt K., Lynch C.F., et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 92 (2000) 1165-1171
7. Robinson D., Moller H., and Horwich A. Mortality and incidence of second cancers following treatment for testicular cancer. Br J Cancer 96 (2007) 529-533
8. van den Belt-Dusebout A.W., de Wit R., Gietema J.A., Horenblas S., Louwman M.W., Ribot J.G., et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25 (2007) 4370-4378
9. Travis L.B., Fossa S.D., Schonfeld S.J., McMaster M.L., Lynch C.F., Storm H., et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97 (2005) 1354-1365
10. In: Parkin D.M., Muir C.S., Whelan S.L., Ferlay J., Teppo L., and Thomas D.B. (Eds). Cancer incidence in five continents. Vol. 8. No. 155 (2002), International Agency for Research on Cancer, Lyon (France)
11. Richiardi L., Scélo G., Boffetta P., Hemminki K., Pukkala E., Olsen J.H., et al. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer 120 (2006) 623-631
12. Horwich A., Shipley J., and Huddart R. Testicular germ-cell cancer. Lancet 367 (2006) 754-765
13. Huddart R.A., and Birtle A.J. Recent advances in the treatment of testicular cancer. Expert Rev Anticancer Ther 5 (2005) 123-138
14. Preston D.L., Lubin J.H., and Pierce D.A. EPICURE user's guide (1991), HiroSoft International Corporation, Seattle (WA)
15. Hanks G.E., Peters T., and Owen J. Seminoma of the testis: long term beneficial and deleterious results of radiation. Int J Radiat Oncol Biol Phys 24 (1992) 913-919
16. Thomas G.M. Over 20 years progress in radiation oncology: seminoma. Semin Radiat Oncol 7 (1997) 135-145
17. Nichols C.R., Breeden E.S., Loehrer P.J., Williams S.D., and Einhorn L.H. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst 85 (1993) 36-40
18. Bokemeyer C., Schmoll H.J., Kuczyk M.A., Beyer J., and Siegert W. Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J Natl Cancer Inst 87 (1995) 58-60
19. Mattson B., and Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 23 (1984) 305-313
20. Hakulinen T. Methodological problems in comparing incidence and prevalence of leukaemias and lymphomas: ascertainment and age adjustment. Leukemia 13 Suppl. 1 (1999) S37-S41
21. Astrom M., Bodin L., and Tidefelt U. Adjustment of incidence rates after an estimate of completeness and accuracy in registration of acute leukemias in a Swedish population. Leuk Lymphoma 41 (2001) 559-570
22. In: Curtis R.E., Freedman D.M., Ron E., Ries L.A.G., Hacker D.G., Edwards B.K., et al. (Eds). New malignancies among cancer survivors: SEER cancer registries1973-2000 (NIH Publication No. 05-5302) (2006), National Cancer Institute, Bethesda (MD)